At BioVie, our quest for innovation is driven by a deep-seated commitment to addressing some of the most pressing medical challenges of our times.
We are tirelessly developing transformative treatments for age-related diseases. But beyond treating symptoms, our approach targets the root causes. By leveraging cutting-edge biotechnologies, we delve deep into cellular mechanisms and genetic pathways.
Our lead asset, bezisterim (NE3107), is a novel, orally administered small molecule that is both anti-inflammatory and insulin-sensitizing, and is currently being studied in Alzheimer’s disease, Parkinson’s disease and Long COVID. As part of the clinical trials in these core indications, we’re also exploring bezisterim’s potential impact on longevity by measuring its ability to reduce DNA methylation in study participants.
We are also investigating BIV201 for the treatment of ascites. BIV201 is a novel, continuous infusion formulation of terlipressin delivered via a small, portable pump that patients can wear while engaging in typical tasks and activities at home. We believe that BIV201 may have the potential to slow the build-up of ascites fluid in the abdomen, and that it may do so by constricting certain blood vessels, potentially contributing to improved blood flow in the kidneys and liver.
Our groundbreaking publications delve into the promising intersection of critical health challenges, including Parkinson’s disease, Alzheimer’s disease, biological aging processes and ascites/cirrhosis. Through our publications, we explore our innovative approaches and outline findings that can advance our understanding and treatment of these complex and debilitating conditions.
At BioVie, our commitment to advancing healthcare through scientific innovation is demonstrated daily through our robust research and development initiatives. Central to this are our clinical trials – crucial, scientifically rigorous testing processes designed to evaluate the safety, effectiveness, and optimal usage of new medical interventions.
